Compare Aspen Aerogels Inc (ASPN) vs Nuvalent Inc (NUVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aspen Aerogels Inc vs Nuvalent Inc — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while Nuvalent Inc trades at $123.9 (market cap $9.80B). The key difference: Nuvalent Inc is far larger — about 22.9× Aspen Aerogels Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.
| ASPN | NUVL | |
|---|---|---|
Market Cap | $427.65M | $9.80B |
Sector | Technology | Technology |
52-Week High | $8.82 | $123.90 |
52-Week Low | $2.57 | $72.16 |
Enterprise Value | $382.60M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
Nuvalent (NUVL) trades at $123.9, up 0.06% on the day, following GSK's $10.6 billion all-cash acquisition offer at $124 per share announced on June 9, 2026 (Reuters). The stock is near the acquisition price, with bullish technical signals from moving averages but overbought RSI readings. Financially, the company reports negative earnings and cash flow from operations, with a P/B ratio of 8.35. Recent news highlights multiple law firms investigating the fairness of the deal.
The acquisition by GSK provides a clear exit near current levels, limiting upside but reducing volatility. Key risks include deal completion uncertainty and shareholder litigation. Analyst sentiment is mixed with 42% buy ratings. Investors should weigh the guaranteed offer against fundamental weaknesses and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
